The estimated Net Worth of Derace L Schaffer is at least $3.35 Million dollars as of 5 June 2019. Derace Schaffer owns over 10,000 units of Lantheus Inc stock worth over $1,732,538 and over the last 9 years Derace sold LNTH stock worth over $1,617,850.
Derace has made over 16 trades of the Lantheus Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Derace sold 10,000 units of LNTH stock worth $247,100 on 5 June 2019.
The largest trade Derace's ever made was buying 147,130 units of Lantheus Inc stock on 22 December 2017 worth over $258,949. On average, Derace trades about 25,685 units every 34 days since 2016. As of 5 June 2019 Derace still owns at least 16,994 units of Lantheus Inc stock.
You can see the complete history of Derace Schaffer stock trades at the bottom of the page.
Derace's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA, MA, 01862.
Over the last 9 years, insiders at Lantheus Inc have traded over $500,725,766 worth of Lantheus Inc stock and bought 8,000 units worth $141,200 . The most active insiders traders include David F Burgstahler, Capital Partners Gp, Llc Av..., and Sriram Venkataraman. On average, Lantheus Inc executives and independent directors trade stock every 11 days with the average trade being worth of $15,777,680. The most recent stock trade was executed by James H Thrall on 21 August 2024, trading 1,000 units of LNTH stock currently worth $98,520.
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
Lantheus Inc executives and other stock owners filed with the SEC include: